| Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy A Abdel-Gadir, E Stephen-Victor, GK Gerber, M Noval Rivas, S Wang, ... Nature medicine 25 (7), 1164-1174, 2019 | 294 | 2019 |
| Lipid-antigen presentation by CD1d+ B cells is essential for the maintenance of invariant natural killer T cells A Bosma, A Abdel-Gadir, DA Isenberg, EC Jury, C Mauri Immunity 36 (3), 477-490, 2012 | 236 | 2012 |
| Probiotics: reiterating what they are and what they are not G Reid, AA Gadir, R Dhir Frontiers in microbiology 10, 444972, 2019 | 179 | 2019 |
| Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity OT Burton, SL Logsdon, JS Zhou, J Medina-Tamayo, A Abdel-Gadir, ... Journal of allergy and clinical immunology 134 (6), 1310-1317. e6, 2014 | 167 | 2014 |
| Regulatory T cell-derived TGF-β1 controls multiple checkpoints governing allergy and autoimmunity JA Turner, E Stephen-Victor, S Wang, MN Rivas, A Abdel-Gadir, H Harb, ... Immunity 53 (6), 1202-1214. e6, 2020 | 100 | 2020 |
| Oral Immunotherapy With Omalizumab Reverses the Th2 Cell‐Like Program of Regulatory T cells and Restores their Function A Abdel‐Gadir, L Schneider, A Casini, LM Charbonnier, SV Little, ... Clinical & Experimental Allergy, 2018 | 73 | 2018 |
| Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab CSK Yee, S Albuhairi, E Noh, K El-Khoury, S Rezaei, A Abdel-Gadir, ... The Journal of Allergy and Clinical Immunology: In Practice 7 (2), 451-461. e7, 2019 | 60 | 2019 |
| Antigen-specific Treg cells in immunological tolerance: implications for allergic diseases A Abdel-Gadir, AH Massoud, TA Chatila F1000Research 7, 2018 | 56 | 2018 |
| Vitamin D3 treatment of vitamin D–insufficient asthmatic patients does not alter immune cell function B Reid, PO Girodet, JS Boomer, A Abdel-Gadir, K Zheng, ME Wechsler, ... Journal of Allergy and Clinical Immunology 138 (1), 286-289. e9, 2016 | 8 | 2016 |
| Therapeutic microbiota for the treatment and/or prevention of food allergy TA Chatila, L Bry, G Gerber, A Abdel-Gadir, R Rachid US Patent 10,391,131, 2019 | 6 | 2019 |
| Deconstructing then priming gut microbiota resilience G Reid, A Gadir, S Puebla Barragan, R Dhir OBM Hepatology and Gastroenterology 5 (1), 1-9, 2021 | 5 | 2021 |
| Therapeutic microbiota for the treatment and/or prevention of food allergy TA Chatila, L Bry, G Gerber, A Abdel-Gadir, R Rachid US Patent 10,898,527, 2021 | 2 | 2021 |
| Capacity of a Microbial Synbiotic To Rescue the In Vitro Metabolic Activity of the Gut Microbiome following Perturbation with Alcohol or Antibiotics BT Tierney, P Van den Abbeele, GA Al-Ghalith, L Verstrepen, ... Applied and Environmental Microbiology 89 (3), e01880-22, 2023 | 1 | 2023 |
| Compositions and methods of improving the skin microbiome R Dhir, AL Almada, AA Gadir US Patent App. 17/089,469, 2021 | 1 | 2021 |
| Therapeutic microbiota for the treatment and/or prevention of food allergy TA Chatila, L Bry, G Gerber, A Abdel-Gadir, R Rachid US Patent App. 16/568,711, 2020 | 1 | 2020 |
| Compositions and methods of improving the skin microbiome R Dhir, AL Almada, AA Gadir US Patent App. 18/518,528, 2024 | | 2024 |
| Methods and compositions for treating or preventing an allergy or anaphylaxis TA Chatila, E Crestani, ES VICTOR, A Abdel-Gadir, R Rachid US Patent App. 17/801,238, 2023 | | 2023 |
| Therapeutic microbiota for the treatment and/or prevention of dysbiosis TA Chatila, A Abdel-Gadir, ES VICTOR, R Rachid, L Bry, G Gerber US Patent App. 17/442,904, 2022 | | 2022 |
| Therapeutic microbiota for the treatment and/or prevention of food allergy TA Chatila, L Bry, G Gerber, A Abdel-Gadir, R Rachid US Patent App. 17/381,843, 2022 | | 2022 |
| Therapeutic microbiota for the treatment and/or prevention of dysbiosis L Bry, TA Chatila, G Gerber, A Abdel-Gadir, R Rachid US Patent App. 17/292,482, 2022 | | 2022 |
Talal ChatilaHarvard Medical School; Boston Children's HospitalVerified email at childrens.harvard.edu
